1082 related articles for article (PubMed ID: 29376560)
1. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
[TBL] [Abstract][Full Text] [Related]
2. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
Uhlig K; Efremov L; Tongers J; Frantz S; Mikolajczyk R; Sedding D; Schumann J
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD009669. PubMed ID: 33152122
[TBL] [Abstract][Full Text] [Related]
3. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease.
Burkhardt BE; Rücker G; Stiller B
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009515. PubMed ID: 25806562
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Hummel J; Rücker G; Stiller B
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011312. PubMed ID: 28262914
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic levosimendan for the prevention of low cardiac output syndrome and mortality in paediatric patients undergoing surgery for congenital heart disease.
Hummel J; Rücker G; Stiller B
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011312. PubMed ID: 28770972
[TBL] [Abstract][Full Text] [Related]
7. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Fuhrmann JT; Schmeisser A; Schulze MR; Wunderlich C; Schoen SP; Rauwolf T; Weinbrenner C; Strasser RH
Crit Care Med; 2008 Aug; 36(8):2257-66. PubMed ID: 18664782
[TBL] [Abstract][Full Text] [Related]
8. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty.
Samimi-Fard S; García-González MJ; Domínguez-Rodríguez A; Abreu-González P
Int J Cardiol; 2008 Jul; 127(2):284-7. PubMed ID: 17643519
[TBL] [Abstract][Full Text] [Related]
9. Mechanical assist devices for acute cardiogenic shock.
Ni hIci T; Boardman HM; Baig K; Stafford JL; Cernei C; Bodger O; Westaby S
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD013002. PubMed ID: 32496607
[TBL] [Abstract][Full Text] [Related]
10. Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series.
Malliotakis P; Xenikakis T; Linardakis M; Hassoulas J
Hellenic J Cardiol; 2007; 48(2):80-8. PubMed ID: 17489345
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
[TBL] [Abstract][Full Text] [Related]
12. Levosimendan neither improves nor worsens mortality in patients with cardiogenic shock due to ST-elevation myocardial infarction.
Omerovic E; Råmunddal T; Albertsson P; Holmberg M; Hallgren P; Boren J; Grip L; Matejka G
Vasc Health Risk Manag; 2010 Sep; 6():657-63. PubMed ID: 20859537
[TBL] [Abstract][Full Text] [Related]
13. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
El Mokhtari NE; Arlt A; Meissner A; Lins M
Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
Beute J
Crit Care Med; 2009 Sep; 37(9):2678; author reply 2678-9. PubMed ID: 19687655
[No Abstract] [Full Text] [Related]
15. Cardiogenic shock after primary percutaneous coronary intervention: Effects of levosimendan compared with dobutamine on haemodynamics.
García-González MJ; Domínguez-Rodríguez A; Ferrer-Hita JJ; Abreu-González P; Muñoz MB
Eur J Heart Fail; 2006 Nov; 8(7):723-8. PubMed ID: 16492404
[TBL] [Abstract][Full Text] [Related]
16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
17. Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.
Gong B; Li Z; Yat Wong PC
J Cardiothorac Vasc Anesth; 2015 Dec; 29(6):1415-25. PubMed ID: 26275522
[TBL] [Abstract][Full Text] [Related]
18. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome].
Levin RL; Degrange MA; Porcile R; Salvagio F; Blanco N; Botbol AL; Tanus E; del Mazo CD
Rev Esp Cardiol; 2008 May; 61(5):471-9. PubMed ID: 18462650
[TBL] [Abstract][Full Text] [Related]
19. Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgery.
Zhao N; Xu J; Singh B; Yu X; Wu T; Huang Y
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010726. PubMed ID: 27488764
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan].
Zobel C; Reuter H; Schwinger RH
Med Klin (Munich); 2004 Dec; 99(12):742-6. PubMed ID: 15599685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
